Year None20262025202420232022202120202019 Jul 08, 2026 FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Jul 02, 2026 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 30, 2026 Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with C Jun 29, 2026 FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Chil Jun 05, 2026 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 03, 2026 New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital May 26, 2026 Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference May 08, 2026 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 06, 2026 Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 9 of 27